Log in

NASDAQ:APVO - Aptevo Therapeutics Stock Price, Forecast & News

$0.63
0.00 (0.00 %)
(As of 01/29/2020 01:32 AM ET)
Today's Range
$0.61
Now: $0.63
$0.65
50-Day Range
$0.54
MA: $0.62
$0.70
52-Week Range
$0.49
Now: $0.63
$2.00
Volume221,154 shs
Average Volume371,538 shs
Market Capitalization$28.59 million
P/E RatioN/A
Dividend YieldN/A
Beta2.49
Aptevo Therapeutics Inc, a clinical-stage biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed product includes IXINITY, a coagulation factor IX therapeutic indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:APVO
CUSIPN/A
Phone206-838-0500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$23.07 million
Book Value$1.33 per share

Profitability

Net Income$-53,690,000.00
Net Margins-156.03%

Miscellaneous

Employees118
Market Cap$28.59 million
Next Earnings Date3/16/2020 (Estimated)
OptionableOptionable

Receive APVO News and Ratings via Email

Sign-up to receive the latest news and ratings for APVO and its competitors with MarketBeat's FREE daily newsletter.


Aptevo Therapeutics (NASDAQ:APVO) Frequently Asked Questions

What is Aptevo Therapeutics' stock symbol?

Aptevo Therapeutics trades on the NASDAQ under the ticker symbol "APVO."

How were Aptevo Therapeutics' earnings last quarter?

Aptevo Therapeutics Inc (NASDAQ:APVO) issued its quarterly earnings results on Thursday, November, 7th. The biotechnology company reported ($0.23) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.24) by $0.01. The biotechnology company had revenue of $9.01 million for the quarter, compared to analyst estimates of $8.05 million. Aptevo Therapeutics had a negative net margin of 156.03% and a negative return on equity of 171.99%. View Aptevo Therapeutics' Earnings History.

When is Aptevo Therapeutics' next earnings date?

Aptevo Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Aptevo Therapeutics.

What price target have analysts set for APVO?

2 analysts have issued 1 year target prices for Aptevo Therapeutics' stock. Their forecasts range from $3.00 to $3.00. On average, they anticipate Aptevo Therapeutics' share price to reach $3.00 in the next twelve months. This suggests a possible upside of 375.1% from the stock's current price. View Analyst Price Targets for Aptevo Therapeutics.

What is the consensus analysts' recommendation for Aptevo Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptevo Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aptevo Therapeutics.

Has Aptevo Therapeutics been receiving favorable news coverage?

News headlines about APVO stock have trended extremely negative on Wednesday, InfoTrie Sentiment reports. The research firm rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Aptevo Therapeutics earned a media sentiment score of -4.3 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Aptevo Therapeutics.

Who are some of Aptevo Therapeutics' key competitors?

What other stocks do shareholders of Aptevo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptevo Therapeutics investors own include Zynerba Pharmaceuticals (ZYNE), Advanced Micro Devices (AMD), Corbus Pharmaceuticals (CRBP), NVIDIA (NVDA), Synergy Pharmaceuticals (SGYP), AbbVie (ABBV), Alibaba Group (BABA), AVEO Pharmaceuticals (AVEO), BIOLINERX LTD/S (BLRX) and Exelixis (EXEL).

Who are Aptevo Therapeutics' key executives?

Aptevo Therapeutics' management team includes the folowing people:
  • Mr. Marvin L. White, Pres, CEO & Director (Age 57)
  • Mr. Jeffrey G. Lamothe, Sr. VP, CFO & Treasurer (Age 53)
  • Dr. Scott C. Stromatt, Sr. VP of Clinical Devel. & Medical Affairs and Chief Medical Officer (Age 61)
  • Mr. Randy Joe Maddux, Sr. VP of Operations & Chief Manufacturing Officer (Age 58)
  • Dr. Jane A. Gross, Sr. VP & Chief Scientific Officer (Age 62)

How do I buy shares of Aptevo Therapeutics?

Shares of APVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Aptevo Therapeutics' stock price today?

One share of APVO stock can currently be purchased for approximately $0.63.

How big of a company is Aptevo Therapeutics?

Aptevo Therapeutics has a market capitalization of $28.59 million and generates $23.07 million in revenue each year. The biotechnology company earns $-53,690,000.00 in net income (profit) each year or ($2.39) on an earnings per share basis. Aptevo Therapeutics employs 118 workers across the globe.View Additional Information About Aptevo Therapeutics.

What is Aptevo Therapeutics' official website?

The official website for Aptevo Therapeutics is http://www.aptevotherapeutics.com/.

How can I contact Aptevo Therapeutics?

Aptevo Therapeutics' mailing address is 2401 4TH AVENUE SUITE 1050, SEATTLE WA, 98121. The biotechnology company can be reached via phone at 206-838-0500 or via email at [email protected]


MarketBeat Community Rating for Aptevo Therapeutics (NASDAQ APVO)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  158 (Vote Outperform)
Underperform Votes:  173 (Vote Underperform)
Total Votes:  331
MarketBeat's community ratings are surveys of what our community members think about Aptevo Therapeutics and other stocks. Vote "Outperform" if you believe APVO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APVO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel